Hydrolysable Anesthetic-Polymer Conjugates for Long Nerve Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional local anesthetics have a short duration of action and cause significant side effects, including local and systemic toxicity, which are exacerbated by sustained release vehicles, and there is a need for a formulation that can prolong nerve blockade with minimal toxicity.
Innovation Solution
A covalent anesthetic-polymer conjugate is developed, where anesthetic agents like tetrodotoxin are covalently bound to biodegradable and biocompatible polymers via hydrolysable linkages, allowing for controlled release of anesthetics over a prolonged period, up to one month, with reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional local anesthetics are used to achieve effective nerve blockade, then the duration of action is sufficient for short-term procedures, but the duration is too short for chronic and neuropathic pain management
Solution Approach 1:
The anesthetic is covalently conjugated to the polymer backbone in advance, creating a reservoir that releases the anesthetic slowly over time. This preliminary bonding action enables prolonged duration of action (up to one month) while maintaining reliable pain management for chronic conditions.
2Duration of action of moving object
If higher concentrations of conventional local anesthetics are used to prolong nerve blockade, then the duration of action increases, but local and systemic toxicity increases
Solution Approach 1:
The invention changes the delivery parameter from high concentration bolus injection to low concentration sustained release. The covalent conjugate releases anesthetic at controlled low concentrations over extended periods, achieving prolonged duration of action while maintaining toxicity levels below those of conventional high-dose administrations.
3Duration of action of moving object
If sustained release vehicles are used to deliver anesthetics to prolong duration, then the duration of nerve blockade increases, but inflammatory responses at the nerve are worsened
Solution Approach 1:
The invention uses a composite structure where the anesthetic is covalently bonded to a polymer backbone. This composite material provides sustained release capability without the inflammatory side effects associated with conventional sustained release vehicles, achieving prolonged duration of action with improved biocompatibility.
4Reliability
If TTX is used at doses required to achieve significant peripheral nerve blockade, then the local anesthetic effect is potent, but systemic side effects such as hypotension and respiratory failure occur
Solution Approach 1:
The covalent conjugate changes the delivery parameters of TTX from high-dose acute administration to low-dose sustained release. This enables the polymer-conjugated TTX to achieve significant peripheral nerve blockade with reduced systemic toxicity, as the anesthetic is released slowly at sub-toxic concentrations over time.
5Duration of action of moving object
If liposomal formulations are used to encapsulate TTX for controlled release, then the duration of nerve blockade is prolonged, but the initial burst release prevents further dose increases
Solution Approach 1:
The covalent polymer-anesthetic conjugate provides a superior composite structure compared to liposomal encapsulation. The covalent bonding prevents burst release entirely, enabling both prolonged duration of action and higher total doses of TTX to be administered safely, overcoming the dose-limiting burst release problem of liposomal formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate provides effective nerve blockade for up to one month with minimal systemic and local toxicity, enabling tunable release based on polymer hydrophilicity adjustments, and can include additional therapeutic agents.
Implementation Method 1
the anesthetic agent is covalently conjugated to the polymer backbone via a hydrolysable linker
Data Source
Figure 1A
Figure 1B~1C
Figure 2A~2C
AI summary
Anesthetics covalently conjugated onto biodegradable and biocompatible hydrophilic polymers via hydrolysable linkages provide controlled release of local anesthetics in vivo in an effective amount for nerve blockade with reduced toxicity relative to the unconjugated anesthetic agent. The rate of anesthetic release can be tuned by changing the hydrophilicity of the polymer. Exemplary formulations of Poly (glycerol sebacate) (PGS), optionally including Poly ethylene glycol (PEG) polymers conjugated to Tetrodotoxin (TTX) (PGS-PEG-TTX and PGS-TTX), and methods of use thereof are provided Nerve blockade from PGS-PEG-TTX and PGS-TTX was associated with minimal systemic and local toxicity to the muscle and the peripheral nerves. TDP-TTX conjugates homogeneously dispersed into PEG200 are also described. PEG200 not only worked as a medium, but also worked as a chemical permeation enhancer (CPE) to enhance the effectiveness of TTX.